IP-protected CBD intermediates offer superior functionality and enable higher drug loading compared to currently marketed products, paving the way for oral dosage forms with enhanced bioavailability. Masu. This enables the development of more convenient and patient-friendly dosage forms, including orally disintegrating tablets (ODTs) and chewable tablets, and CBtru is a leader in cannabinoid innovation with the ability to transform CBD-based therapeutics. This is an important advance.
Exploring new frontiers in CBD drug development
Existing CBD-based medicines have limited oral bioavailability (as low as 6% in humans) due to the low solubility and absorption of the cannabinoid molecule, and therefore low efficacy. As a result, large amounts of CBD are required to have a therapeutic effect, requiring administration through oil-based oral solutions, which can be inconvenient and uncomfortable for patients to ingest. dsm-firmenich says its advanced formulation CBD drug intermediates aim to address this challenge. This allows for higher active loads, improved stability, and optimized pharmacokinetic performance, allowing for the creation of more bioavailable and patient-friendly dosage forms.
Molecules with immense therapeutic potential
“We are committed to improving the health of patients around the world by unlocking new therapeutic possibilities and increasing product acceptance and compliance. “We have invested in a molecule with tremendous therapeutic potential, as evidenced by the changing favorable regulatory environment,” said Athanasia Kanli, global business development manager for pharmaceuticals at dsm-firmenich. Ta.
“To date, CBD applications have been limited to oil-based delivery systems, primarily due to its low bioavailability and physical and chemical instability. This gives us the opportunity to rapidly expand This led to the introduction of CBtru to the cannabinoid market, and its advanced features facilitate the development of faster-acting, more effective and patient-friendly treatments, representing a new era in cannabinoid-based medicines. Masu.”
The result of two years of intensive research
dsm-firmenich's new CBD pharmaceutical intermediate is the result of two years of intensive research. During this period, the company's technology team rigorously evaluated over 200 prototypes and multiple drug delivery technologies to identify a CBD solution with superior performance. Going forward, dsm-firmenich hopes to establish a long-term strategic partnership to explore new therapeutic applications utilizing the investigational CBtru formulation.
Beyond CBtru
In collaboration with Brains Bioceutical, a manufacturer of high-quality pharmaceutical-grade cannabinoids, dsm-firmenich has developed an end-to-end product designed to support early-stage cannabinoid drug development and realize the potential of CBD-based formulations. We provide an end innovation platform. Its capabilities include cutting-edge formulation expertise, a global network of regulatory experts, and proficiency in preclinical and clinical research. The company also has the ability to provide customized solutions depending on therapeutic areas and drug delivery objectives.
